|
注册号: Registration number: |
ChiCTR2500100838 |
|
最近更新日期: Date of Last Refreshed on: |
2025-04-16 09:06:45 |
|
注册时间: Date of Registration: |
2025-04-16 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
榫卯式角膜缘切口白内障超声乳化术临床研究 |
|
Public title: |
A clinical research of the phacoemulsification cataract surgery with the mortise and tenon limbal incision |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
榫卯式角膜缘切口白内障超声乳化术临床研究 |
|
Scientific title: |
A clinical research of the phacoemulsification cataract surgery with the mortise and tenon limbal incision |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陈瑞博 |
研究负责人: |
陈兵 |
|
Applicant: |
Ruibo Chen |
Study leader: |
Bing Chen |
|
申请注册联系人电话: Applicant telephone: |
+86 188 5110 1267 |
研究负责人电话:
Study leader's |
+86 138 1369 7258 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1605573003@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
chenbing751@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
南京市鼓楼区中央门街道东南大学丁家桥校区 |
研究负责人通讯地址: |
福建省厦门市思明区厦禾路336号厦门眼科中心 |
|
Applicant address: |
Southeast University Dingjiaqiao Campus, No. 87 Dingjiaqiao, Gulou District, Nanjing, China |
Study leader's address: |
Xiamen Eye Center, No. 336, Xiahe Road, Siming District, Xiamen, Fujian, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
东南大学医学院 |
||
|
Applicant's institution: |
Southeast University School of medicine |
||
|
研究负责人所在单位: |
厦门大学附属厦门眼科中心 |
||
|
Affiliation of the Leader: |
Xiamen Eye Center, Xiamen University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
XMYKZX-KY-2025-024 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
厦门大学附属厦门眼科中心临床研究医学伦理审查会 |
||
|
Name of the ethic committee: |
Medical Ethics Review Meeting for Clinical Research at Xiamen Eye Center, Xiamen University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-04-09 00:00:00 | ||
|
伦理委员会联系人: |
黎晓新 |
||
|
Contact Name of the ethic committee: |
Xiaoxin Li |
||
|
伦理委员会联系地址: |
福建省厦门市思明区厦禾路336号厦门眼科中心 |
||
|
Contact Address of the ethic committee: |
Xiamen Eye Center, No. 336, Xiahe Road, Siming District, Xiamen, Fujian, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 592 210 9882 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
厦门大学附属厦门眼科中心 |
||||||||||||||||||||||
|
Primary sponsor: |
Xiamen Eye Center, Xiamen University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
福建省厦门市思明区厦禾路336号厦门眼科中心 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Xiamen Eye Center, No. 336, Xiahe Road, Siming District, Xiamen, Fujian, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
self-finance |
||||||||||||||||||||||
|
研究疾病: |
白内障 |
||||||||||||||||||||||
|
Target disease: |
Cataract |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
治疗新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
New Treatment Measure Clinical Study |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
30年以来,白内障超声乳化手术日益成熟,已经成为白内障手术的金标准1–3。白内障手术已经从复明手术过渡到屈光性白内障手术,同时患者对于术中安全性、术后视觉质量(如术源性高阶像差、术源性玻璃体混浊、术源性黄斑前膜等)以及尽可能低的术源性散光(SIA)的期望值也日益提高。而上述问题的出现与白内障手术切口密切相关,如何减少或解决这些问题,改变手术切口至关重要。白内障超声乳化术常见的切口类型包括透明角膜切口和巩膜隧道切口。近年来的研究表明,透明角膜切口(CCI)因其更好的适用性4和较少的术后炎症5而被广泛采用;相比较而言,巩膜隧道切口因其经巩膜隧道切口行超声乳化难度相对较大6而被逐渐减少使用率。 |
||||||||||||||||||||||
|
Objectives of Study: |
Over the past 30 years, phacoemulsification cataract surgery (PHACO) has undergone significant advancements, becoming the gold standard for cataract treatment[1–3]. Cataract surgery has evolved from a vision-restoring procedure to a refractive cataract surgery, with patients' expectations regarding intraoperative safety, enhanced postoperative visual quality (including concerns about surgically induced higher-order aberrations, vitreous opacity, and epiretinal macular membranes), and minimized surgically induced astigmatism (SIA). These concerns are closely related to the types of incisions employed in cataract surgery. Therefore, modifying the surgical incision is essential to addressing and mitigating these issues. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.既往蚕食性角膜炎或者边缘性角膜炎等角膜缘变性变薄的患者; 2.眼外伤史; 3.不能耐受局部麻醉而不能配合手术的; 4.眼球震颤; 5.其他白内障超声乳化手术禁忌症; 6.既往有或玻璃体视网膜手术、翼状胬肉切除术或者角膜屈光手术等眼部手术史。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with a history of rodent corneal ulcer or peripheral ulcerative keratitis or other conditions associated with limbal thining; 2. History of ocular trauma; 3. Patients unable to tolerate local anesthesia or cooperate with surgery; 4. congenital nystagmus; 5. Other Contraindications of phacoemulsification cataract surgery; 6. History of vitreoretinal surgery, pterygium excision, keratorefractive surgery, or other ocular surgeries. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-04-17 00:00:00至 To 2026-04-17 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-04-17 00:00:00 至 To 2026-04-17 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
利用随机化软件生成随机数字表 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Generation of random number tables using randomization software |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
单盲,即患者不知道自己被分到哪一组 |
|
Blinding: |
Single-blind, i.e., patients do not know which group they are assigned to |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
以论文形式呈现 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Presented in the form of a paper |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Sheet |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |